To characterize cell surface molecules involved in control of growth of malignant lymphocytes, monoclonal antibodies were raised against the human B lymphoblast cell line SKW6.4. One monoclonal antibody, anti-APO-1, reacted with a 52-kilodalton antigen (APO-1) on a set of activated human lymphocytes, on malignant human lymphocyte lines, and on some patient-derived leukemic cells. Nanogram quantities of anti-APO-l completely blocked proliferation of cells bearing APO- polyacrylamide gel electrophoresis (SDS-PAGE) as a main band of 52 kD (Fig. 1) . Apart from actin (43 kD), which was nonspecifically precipitated with IgG3, anti-APO-1 specifically immunoprecipitated a minor band of 25 kD. This 25-kD protein might either represent a degradation product or be noncovalently associated with the 52-kD protein.
To characterize cell surface molecules involved in control of growth of malignant lymphocytes, monoclonal antibodies were raised against the human B lymphoblast cell line SKW6. 4 (1) . Apoptosis is the most common form of eukaryotic cell death and occurs in embryogenesis, metamorphosis, tissue atrophy, and tumor regression (2) . It is also induced by cytotoxic T lymphocytes and natural killer and killer cells; by cytokines like tumor necrosis factor (TNF) and lymphotoxin (LT); and by glucocorticoids (1, 2). The most characteristic signs of apoptosis are segmentation of the nucleus, condensation of the cytoplasm, membrane blebbing, and DNA fragmentation into multimers of about 180 base pairs (called a "DNA ladder") (1, 2) . To analyze mechanisms of lymphocyte growth control and to interfere with the replication of lymphoid tumor cells we raised monoclonal antibodies (MAbs) against cell surface molecules involved in these processes.
We found one MAb (anti-APO-1) that blocks growth and induces apoptosis of SKW6.4 cells (3) . Anti ( Fig. 2b) . Affinity-purified anti-APO-1 induced growth retardation and cell death (Fig. 2c) Cell death induced by anti-APO-1 was complement-independent and occurred under serum-free culture conditions or in culture medium plus serum inactivated at 56°C for 30 min. It differed from death mediated by complement-dependent lysis by: (i) morphology and formation of a DNA ladder (Fig. 2, a and b) , (ii) exogenous Ca2+ independence (7), and (iii) delayed trypan blue uptake and delayed 5'Cr release from radiolabeled target cells (8) . These experiments indicate that cell death induced by anti-APO-1 is fumndamentally different from antibody-and complement-dependent cell lysis.
To assess the specificity of anti-APO-1, a restricted panel of tumor cell lines was screened for expression of APO-1 and susceptibility to growth inhibition and apoptosis. APO-1 was expressed on various human lymphoid B and T cell lines and was not found on a gibbon or mouse T cell line or a human monocytic cell line (Table 1) . Anti-APO-1 blocked proliferation ofthe APO-1-positive cell lines listed in Table 1 via induction of apoptosis, and formation of a DNA ladder was observed in each case (9) . Expression ofAPO-1 was not restricted to cell lines in vitro but could be found on leukemic cells freshly isolated from patients (Table 1) . Since APO-1 was not found on all leukemic cells it may be possible that anti-APO-l defines a subpopulation of leukemias. We also screened human B and T cells for expression of APO-1. We did not detect APO-1 on resting B cells. However, APO-1 was expressed on activated B cells (Table 1) and IgM secretion was reduced approximately fourfold by 3 days of treatment with anti-APO-1 (10) . Peripheral resting T cells did not express APO-1. Activated T cells, however, expressed APO-1 and anti-APO-1-induced apoptosis and growth inhibition of these cells (Table 1) . Thus, our data suggest that APO-1 is a species-specific antigen expressed on activated or malignant lymphocytes.
The striking effect of anti-APO-1 in vitro prompted us to test its effect on tumor growth in vivo. Although the Epstein-Barr virus (EBV)-negative, Burkitt-like lymphoma BJAB was the least sensitive to anti-APO-1 of the B cell panel in Table 1 1 ). Two days after anti-APO-1 injection, a whitish discoloration of the BJAB tumors was observed that was followed by rapid tumor regression. Macroscopic tumor regression was seen in 10 of 11 treated mice within less than 14 days. The control antibodies had no effect (Fig. 3) . In addition, no tumor regression was observed in the mice carrying OCI.LY1, as expected.
To demonstrate proper localization and enrichment of the injected antibodies, labeled MAbs were visualized by autoradiography of sections of the BJAB tumor tissue (Fig. 4a) MAb therapies. In other therapy schedules, tumor was observed in three of the ten mice however, MAbs are injected repeatedly (13) . in which tumor regression had been ob-
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on August 4, 2009 www.sciencemag.org the margin of the original tumor approximately 3 months after the initial macroscopic tumor regression. One of these tumors was removed and found to express APO-1 by immunofluorescence and to be sensitive to anti-APO-l in vitro at a MAb concentration similar to the original in vitro BJAB tumor cell line (Table 1) .
To determine the histology of the regressing BJAB tumors we prepared thin sections of tumors from MAb-treated nu/nu mice. Ten days after intravenous injection of F1120, BJAB appeared as a solid tumor composed of densely packed large blasts with numerous mitoses, some tumor giant cells, and rare apoptotic figures (Fig. 4b, left  panel) . The tumor was penetrated by host vessels. In contrast, almost all remaining BJAB cells of mice treated with anti-APO-1 (Fig. 4b, right panel) showed severe cytopathic changes including nudear pycnosis and cellular edema most pronounced in perivascular microareas. These morphological changes are characteristic of apoptosis.
Taken together, these data strongly suggest that apoptosis is induced by anti-APO-1 and is the mechanism of death and regression of BJAB tumor cells in vivo. The fact that FII20, which strongly binds to the cell surface of BJAB tumor cells, did not cause regression of BJAB also precludes the possibility that killer cells or complement that might have bound to anti-APO-1 may have been involved in the growth inhibition and tumor regression.
We showed that anti-APO-1 specifically blocked growth and triggered programmed cell death (apoptosis) of a set of activated normal lymphocytes and cells from malignant lymphocyte lines after binding to the cell surface protein antigen APO-1. Recently, it has been shown that anti-CD3 induces apoptosis of immature thymocytes in vitro (14) . Therefore, it has been suggested that CD3-triggered apoptosis might be responsible for negative selection of T cells in the thymus. Since APO-1 is expressed on mature activated lymphocytes, additional experiments will be needed to determine whether the antigen might play a similar role in the downregulation of the immune response and be involved in selection and elimination of lymphocytes. It has previously been shown that LT, TNF, and killer cells with their effector molecules induce apoptotic cell death (15) . As anti-APO-1 also induces apoptosis a number of possibilities might be considered for the physiological role ofthe APO-1 antigen. APO-1 might be a receptor for cytotoxic molecules or for autocrine growth factors. Alternatively, it could be a molecule essential for vertical or lateral growth signal transduction. Thus, anti-APO-1 might trigger receptors for lytic molecules or block receptors for growth signals.
Apoptosis is found in all tissues and also in cells from lower organisms (16) . It is conceivable, therefore, that several distinct cell surface antigens with a different tissue distribution are involved in the induction of apoptosis. Elucidation of the structure of APO-1, its possible connection to the cytoskeleton and the molecular events following anti-APO-1 binding might resolve some of these issues.
Our data might also have clinical relevance. APO-1 was found on some lymphoid tumor cells freshly isolated from patients. Thus, anti-APO-1 might be usefufl as a diagnostic tool to define subsets of normal and malignant lymphocytes. In addition, induction of apoptosis may have implications for anti-tumor therapy. Antibodies have frequently been used as heteroconjugates with toxins or drugs to destroy tumor cells (17) . Our data, however, show that MAb alone can be lethal to target cells. Anti-APO-1 and related MAbs might, therefore, be considered for ex vivo or in vivo therapy, under conditions where reactivity with vital normal cells can be excluded or tolerated. Finally, the molecular investigation of cell death induced by anti-APO-1 might lead to a general understanding of apoptosis. In this case, the use of modified or normal physiological ligands to the cell surface antigen initiating apoptosis or of chemicals interfering with the apoptotic signal might be envisaged. 1A) and reverse transcriptase (RT) activity (Fig. 1B) , was seen. Similar results were obtained in seven additional AIDS patients. Delayed expression of HIV-1 in cells that were initially 99% CD3-cells (Fig. 1B) was due to outgrowth of the few contaminating CD3+ cells. Phenotypic analysis of noncocultivated enriched CD3-cells grown wuder the same conditions revealed that 35 to 65% ofthe cells were CD3+ by day 10 in culture.
In the second series of experiments, PBMCs from AIDS patients were doublestained with FITC-conjugated anti-CD3 and anti-CD4 and sorted by FACS into CD3+/CD4+ and CD3+/CD4-populations. These sorted cells were cocultivated with an excess of normal PHA-stimulated blast cells and showed a predominance of HIV-1 expression in the highly enriched (98 to 99%) CD4+ T cell population as determined by the time to peak syncytia formation (Fig. IC) and RT activity (Fig. ID) . Similar results were obtained in seven additional AIDS patients. The phenotypic analysis of freshly sorted CD3+/CD4+ cells revealed a greater than 98 to 99% CD4+ purity in most experiments when stained with the monoclonal antibody to Leu 3a. Again, the delayed expression of HIV-1 in cells that were initially 99% CD4- (Fig.  ID) was most likely due to outgrowth of a few contaminating CD4+ T cells. Phenotypic analysis of non-cocultured enriched CD4-T cells grown under the same conditions revealed that 30 to 55% of the cells were CD4+ by day 10 in culture.
In situ hybridization for HIV-1 viral RNA was then performed at time zero on the highly enriched CD3+/CD4+-and CD3+/CD4--sorted PBMCs. There was a predominance of viral expression in the CD4+ T cell population at a frequency of about 1/1000 cells in four AIDS patients (X ± SEM per 1000 cells was 0.95 ± 0.21) (Fig. 2A) . This is in comparison to a level of viral expression in the CD4-T cell population of <1/100,000 cells (Fig. 2B) , which is equivalent to background signal in controls. The frequency of in situ-positive CD4+ T cells remained unchanged in three of the patients reexamined at 6 to 12 months after the initial studies.
Indirect immunofluorescence studies for HIV-1 viral antigens was also performed at time zero on highly enriched CD3+/CD4+-and CD3+/CD4--sorted PBMCs. These demonstrate a predominance of viral expression in the CD4+ T cell population at a frequency of about 1/1000 cells in four AIDS patients (X ± SEM per 1000 cells was 1.10 ± 0.35 (Fig. 2C) . This is in comparison to a level of viral expression in the CD4-T cell population of < 1/10,000 cells
